Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
AssigneeNew York University
InventorKenneth CADWELL
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of NS1/2 region of murine norovirus MNV or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions, for treating dysbiosis, immune system dysregulation and various disorders, as well as for enhancing mucosal integrity and stimulating IFN-induced genes.
Claims21
-78. (canceled)
A method for treating a subject, the method comprising administering to said subject a therapeutically effective amount of NS1/2 genomic region of murine norovirus (MNV) or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions.
A recombinant vector, recombinant virus, recombinant bacterial or fungal cell, or recombinant bacteriophage comprising NS1/2 genomic region of murine norovirus (MNV) or a corresponding region from a member of the Caliciviridae family, which is optionally a human calicivirus.
A particle comprising NS1/2 genomic region of murine norovirus (MNV) or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions, wherein the particle is optionally a nanoparticle, a liposomal particle, or a virion-like particle.
Dependencies are inferred from the claim text.